“Bimekizumab 3-year Efficacy in High-Impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3/3b Trials” (2024) SKIN The Journal of Cutaneous Medicine, 8(1), p. s304. doi:10.25251/skin.8.supp.304.